Voyager Therapeutics Strategy and Business Model

Executive Overview

Voyager Therapeutics is a precommercial biotechnology company focused on neurological diseases where delivery into the central nervous system remains a major constraint on treatment. Founded in 2013 and headquartered in Lexington, Massachusetts, Voyager has evolved from a more traditional single-program gene therapy developer into a platform-centered company built around proprietary adeno-associated virus (AAV) capsids and vectorized antibody approaches. Its core strategic asset is TRACER, a capsid discovery platform designed to identify AAV variants with better brain targeting and delivery characteristics. As of FY2024, Voyager did not have approved products; its revenue base was driven primarily by collaboration and license arrangements, milestone payments, and the long-term prospect of royalties rather than commercial product sales. Strategically, the company is trying to do two things at once: create its own higher-value neurological pipeline and monetize its delivery technology through partnerships with larger pharmaceutical companies. That makes Voyager unusual among small biotechs. It is not just developing drug candidates; it is also selling access to a differentiated CNS delivery platform that partners can use across multiple future programs.

Voyager Therapeutics at a Glance

Logo
Common name	Voyager Therapeutics
Full legal name	Voyager Therapeutics, Inc.
Headquarters	Lexington, Massachusetts, United States
Ownership	Public company; Nasdaq-listed; ownership is primarily institutional and broadly dispersed
Ticker	VYGR
Exchange	NASDAQ
Market Cap	$224.47M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2013; initial public offering in 2015; collaboration with Neurocrine Biosciences in 2019; Novartis capsid collaboration beginning in 2022; strategic shift in 2023-2024 toward TRACER-enabled platform monetization and vectorized antibody programs
Industry or industries	Biotechnology; genetic medicines; gene therapy; neuroscience
Key products or services	Proprietary AAV capsid discovery and licensing, neurological gene therapy pipeline programs, vectorized antibody programs, research collaboration and development services
Geographic footprint	U.S.-based R&D footprint with global partner reach
Business segments as officially reported	One reportable segment
Company website	https://www.voyagertherapeutics.com

1. What Is the Strategy of Voyager Therapeutics?

Voyager Therapeutics’s public materials through FY2024 describe a company trying to create value at the intersection of neuroscience, gene delivery, and platform partnering. The clearest way to interpret that strategy is through the Playing to Win framework.

1. 1a. What is the winning aspiration of Voyager Therapeutics?

   Voyager Therapeutics’s winning aspiration is to solve the delivery problem in neurological disease well enough to create differentiated genetic medicines and to turn that delivery advantage into a repeatable source of economic value. In practical terms, winning for Voyager does not yet mean maximizing marketed product revenue, because the company remained precommercial as of FY2024. Instead, winning means building a proprietary CNS delivery platform that can produce both wholly owned programs and partner-funded assets, while generating upfront payments, milestones, and eventual royalties from larger pharmaceutical companies.

   The company’s stated emphasis on breaking through barriers in gene therapy and neurology suggests that it is aiming to be more than a single-asset biotech. It wants to be a technology and pipeline company whose capsids and payload design capabilities are valuable across multiple neurological indications.

2. 1b. Where does Voyager Therapeutics play?

   Voyager plays in a relatively narrow but strategically important field: neurological diseases where targeted gene delivery into the brain or central nervous system is hard, and where better delivery could materially improve therapeutic outcomes. Its focus is not broad biotechnology. It is centered on CNS genetic medicines, AAV capsids, and vectorized biologic payloads.

   On the customer side, Voyager currently plays mainly in business-to-business markets by partnering with large biopharmaceutical companies that want access to differentiated AAV capsids or co-developed programs. On the pipeline side, it plays in high-value neurological and neurodegenerative indications where disease biology is difficult, treatment need is high, and successful delivery technology can command strong strategic interest.

3. 1c. How does Voyager Therapeutics plan to win?

   Voyager’s plan to win is based on differentiation, not scale or cost leadership. The company is trying to offer something that many biopharma companies still lack internally: CNS-focused AAV capsids with better delivery characteristics and a platform for combining those capsids with therapeutic payloads, including vectorized antibodies. If that platform works, Voyager can create value in two ways. First, it can advance its own programs with potentially higher retained economics. Second, it can license or partner the technology with larger drug developers that bring capital, development infrastructure, and global commercialization capabilities.

   This model allows Voyager to pursue a hybrid strategy. It is neither a pure tools company nor a pure single-product biotech. The advantage of that model is multiple shots on goal. The challenge is that Voyager must prove platform value repeatedly through preclinical translation, deal terms, and eventually clinical data.

4. 1d. What capabilities must Voyager Therapeutics have in place?

   To make this strategy work, Voyager needs a tightly linked set of capabilities:

   • Proprietary capsid discovery and optimization, especially for CNS targeting
   • Strong translational neuroscience and disease biology expertise
   • AAV vector engineering and payload design, including vectorized antibody know-how
   • Preclinical pharmacology, biodistribution, toxicology, and biomarker capabilities
   • Process development, analytical, and manufacturing oversight for complex genetic medicines
   • Business development and alliance management to structure and run partner relationships
   • Intellectual property management around capsids, payloads, and platform applications

   If any of these capabilities is weak, the model becomes less compelling. In particular, platform companies live or die on the link between technical proof and partnering economics.

5. 1e. What management systems does Voyager Therapeutics require?

   Voyager needs management systems that fit a capital-intensive, high-uncertainty biotech model. That includes milestone-based portfolio review, disciplined cash-runway management, collaboration governance with partners, and strong quality and regulatory controls. Because Voyager’s revenue is lumpy and collaboration-driven, management also needs systems that distinguish accounting revenue from actual cash generation and that prioritize programs according to strategic value, probability of success, and financing impact.

   In practice, this means stage-gate R&D decision making, alliance steering committees, program-level capital allocation, and a risk framework that balances wholly owned upside against the lower-risk economics of partnered assets.

2. What Are the Current Strategic Initiatives of Voyager Therapeutics?

As of FY2024, Voyager Therapeutics’s publicly visible initiatives pointed to a focused agenda rather than a broad pipeline buildout.

• Expand and validate the TRACER capsid platform. Voyager continued to position TRACER as the core strategic asset of the company. The immediate goal is not just scientific publication; it is to generate capsids that are sufficiently differentiated to attract new partners, deepen existing collaborations, and improve the quality of internal programs.
• Advance wholly owned neurological pipeline programs built on better delivery. Voyager has emphasized internal programs that use its capsids and payload engineering capabilities in neurodegeneration and related CNS disease settings. The strategic logic is to retain more long-term value in selected assets while using partnerships elsewhere to control burn.
• Develop vectorized antibody programs. This is one of the more distinctive parts of the current strategy. Rather than relying only on classic gene replacement or gene silencing approaches, Voyager has highlighted AAV-delivered antibodies and antibody-like payloads for neurological targets. If successful, that could combine biologic specificity with more durable CNS exposure.
• Support partner-led programs and capture milestones. Collaborations with larger pharmaceutical companies are not peripheral to the model; they are central to financing it. Voyager’s near- and medium-term economics depend on research support, option and license fees, milestones, and the possibility of future royalties.
• Maintain a selective, capital-conscious operating model. Voyager’s post-pivot strategy has been more selective than the company’s earlier history. The company appears intent on avoiding an overly broad pipeline that would strain cash and management attention before delivery technology is fully validated.

3. What Is the Business Model of Voyager Therapeutics?

Voyager Therapeutics has a biotechnology business model, but not the standard version in which a company funds years of losses in pursuit of a single future product launch. Its model is a hybrid of platform licensing, partnered development, and selectively retained pipeline ownership.

What customers actually buy

Today, Voyager’s paying counterparties are mainly pharmaceutical partners. They buy access to proprietary AAV capsids, research collaboration rights, program options, and licenses to use Voyager’s technology in specific therapeutic settings. In some arrangements, they also fund joint research or development work. If Voyager eventually commercializes a wholly owned product, the end customers would become providers, treatment centers, and ultimately patients, but that is not the current revenue base.

Recurring or repeat-driven versus one-time revenue

The current model is only partly recurring. Upfront license fees are typically one-time. Research funding may recur during the contract term. Milestone revenue is episodic and highly event-driven. Royalties, if they ever arrive, would be the most recurring and attractive part of the model. As of FY2024, Voyager’s revenue profile was therefore economically meaningful but inherently lumpy.

How pricing power works

Voyager’s pricing power rests on differentiation and scarcity. If its capsids truly offer better CNS delivery, better biodistribution, or a more usable route of administration than alternatives, the company can negotiate stronger economics. If the technical edge is modest or unproven, negotiating leverage declines because large pharma companies can wait, pursue alternatives, or build internally.

Why the business mix matters

The mix between partnered programs and wholly owned assets is strategically important. Partnered programs generate earlier cash and reduce risk, but they cap upside. Wholly owned programs preserve more downstream economics, but they require more capital and development execution. Voyager’s model depends on balancing those two poles rather than drifting too far toward either one.

What drives margins and cash generation

For Voyager, gross margin is not the most useful lens because there is no scaled product revenue base. Collaboration revenue can carry relatively low direct cost of goods sold, while operating results are driven mainly by research and development expense, general and administrative expense, and the timing of milestones. Cash generation is therefore a function of partner payments, financing discipline, and the rate at which Voyager advances expensive internal programs.

Revenue model

Voyager’s revenue model is based on collaboration and license revenue, research support, milestone payments, and potential royalties. It is not subscription-based, retail, or transaction-driven in the conventional sense. If the company ever commercializes its own products, those future revenues would likely resemble specialty biopharma product sales, potentially with one-time or infrequent dosing economics.

4. What Products and/or Services Does Voyager Therapeutics Sell?

As of FY2024, Voyager Therapeutics did not sell approved commercial medicines. Its economically important offerings were platform- and pipeline-based.

• TRACER-discovered AAV capsids. These are among Voyager’s most strategically important offerings. They can be licensed to partners for use in selected programs and indications, and they underpin Voyager’s own internal development efforts.
• Wholly owned neurological genetic medicine programs. Voyager develops internal candidates aimed at serious CNS disorders. These programs represent the highest long-term upside if they advance successfully, but they also consume more capital.
• Vectorized antibody programs. Voyager has highlighted the use of AAV vectors to deliver genes encoding therapeutic antibodies or related biologic payloads. This is strategically important because it extends the company beyond classic gene replacement into a broader neurological treatment architecture.
• Collaboration research and development services. In partner arrangements, Voyager also provides research effort, preclinical work, and technology transfer tied to capsid discovery and program advancement.

From a revenue standpoint, the most important current offerings are the collaboration-facing ones: licenses, options, and research arrangements. From a strategic standpoint, the most important newer offerings are the TRACER platform and vectorized antibody capabilities. Compared with Voyager’s earlier history, the center of gravity has shifted away from older surgically delivered neurological gene therapy concepts and toward next-generation delivery and platform monetization.

5. What Are the Key Competitors or Peers of Voyager Therapeutics?

Because Voyager Therapeutics is precommercial and platform-oriented, the best framing is usually closest peers rather than pure direct competitors. Some peers compete on delivery technology, some on CNS gene therapy, and some on neurodegeneration targets.

6. What Is the Marketing Strategy of Voyager Therapeutics?

Voyager Therapeutics does not have a traditional commercial marketing model because it does not yet sell approved products. Its marketing strategy is better understood as scientific reputation building and partner-facing business development.

The company’s main marketing channels are likely to be:

• Scientific communications. Data presentations, publications, and conference visibility are essential because platform credibility drives partnering interest.
• Key opinion leader engagement. In neurology and gene therapy, external scientific validation matters almost as much as internal claims.
• Business development outreach. Voyager’s most important audience today is not consumers; it is pharmaceutical companies evaluating access to differentiated CNS delivery technology.
• Investor communications. For a precommercial biotech, capital-market credibility is part of the broader go-to-market story because financing capacity affects strategic flexibility.

Marketing is therefore a supporting capability rather than the core source of competitive advantage. The real differentiator is the platform. Marketing’s role is to make the science legible, credible, and attractive to partners, investors, and clinical stakeholders.

7. What Are the Key Customer Segments of Voyager Therapeutics?

Voyager’s customer base is atypical because the company is precommercial.

• Large pharmaceutical and biotechnology partners. These are the most important current customers from a revenue standpoint. They pay for access to Voyager’s platform, specific capsids, or program rights.
• Potential future licensing counterparties. Even companies not yet under contract matter strategically because Voyager’s platform model depends on repeat partnering opportunities.
• Clinical investigators and treatment centers. These are not major revenue customers today, but they matter for future trial execution and eventual adoption if Voyager retains commercial rights to any asset.
• Future specialty neurology prescribers and patients. These are prospective end users rather than current customers, but they shape target selection, administration-route choices, and value proposition design.

One important feature of the model is concentration. In many small platform biotechs, a small number of collaboration counterparties can account for most current-period revenue. That concentration can create both leverage and risk.

8. What Is the Sales Model of Voyager Therapeutics?

Voyager Therapeutics’s current sales model is a direct, relationship-driven business development model rather than a broad commercial salesforce model.

Today, its offerings reach customers through:

• Direct licensing and collaboration negotiations. Voyager works directly with pharmaceutical companies to structure access to capsids, programs, and development rights.
• Alliance management and scientific collaboration. Once a deal is signed, revenue realization depends on active scientific execution, governance, and milestone progression.
• Targeted partner development rather than distributor channels. There is no role for conventional distributors or retail channels in the current model.

This channel structure affects growth in several ways. It can produce very large individual deals, but it also makes growth uneven because transaction timing matters. It supports premium pricing if the platform is distinctive, but it requires senior management attention and deep technical selling. It also creates consultant opportunities in partnership strategy, alliance governance, valuation, and operating model design.

If Voyager eventually commercializes its own therapies, the likely sales model would be a focused specialty model centered on neurologists, treatment centers, and referral networks. That remains a forward-looking inference, not the current operating reality.

9. In What Geographies Does Voyager Therapeutics Operate?

Voyager Therapeutics’s physical operating footprint is relatively concentrated, but its economic reach is broader. As of FY2024, the company was headquartered in Lexington, Massachusetts, and remained principally a U.S.-based research and development organization.

Its geographic profile can be understood in three layers:

• Core operations. Research, corporate functions, and strategic management are centered in Massachusetts.
• Development network. Like many biotechnology companies, Voyager relies on external research, manufacturing, and testing partners that may operate across the United States and internationally.
• Commercial reach through partners. Voyager’s collaboration economics can have global relevance because large pharmaceutical partners may seek rights across broad geographies.

So while Voyager is not geographically diversified in the way a multinational manufacturer is, its pipeline and licensing strategy are globally oriented. The company is better described as a U.S.-based innovation platform with worldwide partnering relevance.

10. Who Are the Owners of Voyager Therapeutics?

Voyager Therapeutics is a public company listed on Nasdaq under the ticker VYGR. As of the company’s recent public filings, ownership appeared primarily institutional and broadly dispersed, with no controlling shareholder disclosed. Large passive managers and healthcare-focused investment funds have historically appeared among the more significant holders in public ownership reports, but the company has not been controlled by a single shareholder bloc in the way some venture-backed biotechs are before or immediately after an initial public offering.

11. How Is Voyager Therapeutics Organized?

As of FY2024, Voyager Therapeutics reported one operating and reportable segment. That matters because the economics of the business are managed as one integrated platform and pipeline rather than as separate stand-alone divisions.

At a practical level, the company appears organized around:

• Research and capsid discovery
• Preclinical and translational development
• Technical operations and manufacturing oversight
• Clinical and regulatory activities where applicable
• Business development and alliance management
• Corporate functions such as finance, legal, and administration

Another important organizing principle is the split between wholly owned programs and partnered programs. That distinction often matters more strategically than formal reporting segments because it affects economics, control, and capital requirements.

12. How Does Voyager Therapeutics Operate?

Voyager Therapeutics operates like a specialized neurological genetic medicines developer with a strong platform layer. Day to day, value creation comes from discovering better AAV capsids, matching them with appropriate payloads, generating evidence that the resulting candidates can reach and affect the intended CNS tissues, and then deciding whether to partner or retain each opportunity.

The operating flow typically involves:

1. Discovering or optimizing capsids through the TRACER platform
2. Selecting disease targets and therapeutic payloads
3. Running preclinical pharmacology, biodistribution, safety, and translational studies
4. Managing process development and manufacturing through internal teams and external specialists
5. Preparing regulatory packages for program advancement
6. Structuring and governing collaborations where assets are partnered

The operational bottlenecks are typical of gene therapy but especially acute in CNS delivery: animal-to-human translation, manufacturing consistency, analytical assays, regulatory expectations, and the cost of moving candidates into the clinic. For Voyager, operational excellence is not about factory throughput; it is about technical de-risking and smart portfolio progression.

13. What Are the Growth Opportunities for Voyager Therapeutics?

Voyager Therapeutics’s most plausible growth opportunities are linked to the leverage of a successful platform, not just to a single product outcome.

• More platform partnerships. If TRACER continues to produce differentiated capsids, Voyager could expand the number or scope of collaborations with large pharma companies.
• Higher-value deal economics. Better validation can improve upfronts, milestones, and royalty structures in future agreements.
• Advancing wholly owned CNS programs. Internal assets offer the greatest upside if the company can retain rights long enough to create meaningful clinical value.
• Vectorized antibodies as a new modality layer. This could open target classes and treatment paradigms that are harder to address with standard gene therapy approaches alone.
• Geographic and indication expansion through partners. A single strong delivery technology can be reused across multiple diseases and territories.

The main constraints are equally clear: CNS biology is difficult, manufacturing is specialized, clinical translation is uncertain, and revenue timing can be highly uneven. Voyager’s growth opportunity is real, but it depends on converting scientific differentiation into repeatable economic proof.

14. What Is the History of Voyager Therapeutics?

Voyager Therapeutics was founded in 2013 with venture backing, including support associated with Third Rock Ventures, as a company focused on gene therapy for severe neurological diseases. It went public in 2015, giving it access to public-market capital relatively early in its development.

In its earlier years, Voyager was more closely associated with individual neurological gene therapy programs, including work in Parkinson’s disease and other CNS disorders. Over time, the company broadened its emphasis from single-program development toward platform capabilities in AAV delivery.

A major milestone came in 2019 with a collaboration involving Neurocrine Biosciences, which reinforced the partner-based side of Voyager’s model. Another strategic milestone came with Novartis starting in 2022, reflecting outside validation of Voyager’s capsid technology.

The most important historical shift, however, was strategic rather than transactional: by 2023-2024, Voyager had clearly repositioned itself around next-generation CNS delivery, TRACER-enabled capsid discovery, and vectorized antibody opportunities. That shift effectively changed the company from a narrower neurological gene therapy developer into a platform-led neuroscience biotech.

15. What Are the Key Suppliers to Voyager Therapeutics?

Suppliers are strategically important to Voyager Therapeutics even though it is not yet a large commercial manufacturer. In genetic medicines, the supplier base shapes speed, cost, and development risk.

The most important supplier categories are:

• Contract development and manufacturing organizations (CDMOs). These suppliers help produce viral vectors, development batches, and clinical material.
• Raw material and reagent suppliers. Plasmid DNA, cell culture inputs, and specialized gene therapy materials are critical to development timelines.
• Contract research organizations (CROs). Toxicology, biodistribution, bioanalysis, and animal-model work are often outsourced in part.
• Analytical testing and quality partners. Potency assays, release testing, and characterization work are essential for regulatory progression.
• Specialty logistics providers. High-value, temperature-sensitive biologic materials require controlled transport and chain-of-custody discipline.

Voyager’s public disclosures do not emphasize a concentrated list of named suppliers in the way a mature manufacturer might. Still, supplier structure matters because capacity constraints, regulatory compliance, and batch reliability can directly affect program timelines and value.

16. How Does the Supply Chain of Voyager Therapeutics Function?

Voyager Therapeutics’s supply chain is best understood as a development and clinical supply chain rather than a mass commercial one. It is low-volume, technically complex, and highly quality-sensitive.

The basic flow is:

1. Design and sourcing of plasmids, raw materials, and research inputs
2. Vector manufacturing and purification, often through external partners
3. Analytical characterization, quality control, and release testing
4. Fill-finish and storage under controlled conditions
5. Shipment to research sites, testing locations, or clinical sites as programs advance

For Voyager, supply-chain performance is less about maximizing unit throughput and more about ensuring reproducibility, documentation, and timing. In gene therapy, a delayed or failed batch can have outsized financial and strategic consequences. That is why procurement, technical operations, and quality oversight matter even for a company without commercial-scale sales.

17. What Is the Technology Strategy of Voyager Therapeutics?

Technology is central to Voyager Therapeutics’s competitive position. The company’s most important technology strategy is to build a defensible advantage in CNS-targeted AAV delivery and then use that advantage both internally and externally.

The cornerstone is the TRACER platform, which Voyager uses to discover and evaluate AAV capsids with potentially improved tissue targeting and delivery profiles. This is not just an internal R&D tool. It is also part of the product offering because partners may license access to capsids that emerge from the platform.

Voyager’s technology strategy also includes:

• Engineering payloads that fit the delivery profile of selected capsids
• Developing vectorized antibody approaches for neurological targets
• Generating translational datasets that improve confidence from animal models toward human use
• Building intellectual property around capsids, payload combinations, and therapeutic applications

That makes technology both an internal enabler and a commercial asset. The company is not simply digitizing operations; it is trying to create a core biological technology stack that can support repeated drug creation and repeated partnering.

18. What Is the R&D Strategy of Voyager Therapeutics?

Voyager Therapeutics’s R&D strategy is focused on high-value neurological disease programs where better delivery can materially change the therapeutic profile. The company appears to prefer a smaller number of differentiated programs over a broad catalog of conventional assets.

Several features stand out:

• Delivery-first innovation. Voyager is investing in the platform layer, not just in disease targets. The premise is that better capsids can create better programs.
• Selective internal ownership. The company retains some programs to preserve upside but uses partnerships to avoid carrying the full cost of every asset itself.
• Modality expansion. The vectorized antibody strategy suggests an effort to widen the range of therapeutic payloads beyond traditional gene replacement.
• Translational emphasis. Because CNS delivery is the core challenge, biodistribution, pharmacology, and preclinical-to-clinical translation are especially important.

For Voyager, R&D is not just about finding a target; it is about creating a delivery-and-payload combination that can justify either internal investment or premium partnership economics.

19. What Is the Finance Strategy of Voyager Therapeutics?

Voyager Therapeutics’s finance strategy reflects the realities of a precommercial biotech. The central financial objective is to preserve enough capital to advance the platform and selected programs while reducing reliance on frequent dilutive equity raises.

Key elements include:

• Use partnerships as a financing tool. Upfront payments, research support, and milestones provide non-dilutive capital and help fund internal R&D.
• Maintain portfolio selectivity. Because internal development is expensive, finance strategy and R&D strategy are tightly linked.
• Focus on cash runway more than accounting earnings. For a company like Voyager, operating loss is expected; what matters more is liquidity, burn discipline, and timing of external payments.
• Reinvest rather than distribute capital. Voyager is a growth-stage biotech, so dividends are not the point. Capital is directed toward platform development, pipeline progression, and operating flexibility.

Leverage is not the defining feature of the model. Cash balances, marketable securities, and collaboration economics matter much more than traditional balance-sheet gearing. In that sense, finance strategy is a direct extension of corporate strategy: it exists to buy time, preserve option value, and avoid funding too much risk internally at once.

20. How Companies Like Voyager Therapeutics Leverage Independent Consultants through Umbrex

Voyager Therapeutics operates in a setting where a small management team has to make high-stakes choices about platform strategy, pipeline prioritization, partnering, manufacturing, and capital allocation. That is the kind of environment where targeted use of top independent consultants can be valuable. Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other leading firms. Companies like Voyager use Umbrex when they need that level of problem-solving talent without hiring a full consulting team and its overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI.

For a company like Voyager Therapeutics, representative projects could include:

• Portfolio prioritization across wholly owned programs, partnered assets, and next-wave TRACER opportunities
• Partnership strategy for deciding which indications to retain and which to out-license
• Alliance management support and governance design for large pharmaceutical collaborations
• Commercial assessment of CNS gene therapy and vectorized antibody markets by target, indication, and route of administration
• Manufacturing network strategy, including CDMO selection, tech-transfer planning, and risk management for AAV supply
• R&D operating model redesign to improve stage-gate decisions, cross-functional accountability, and development productivity
• Competitive intelligence on CNS gene therapy, neurodegeneration biologics, and capsid-platform peers
• Pricing, reimbursement, and value-story development for future one-time or long-acting neurological therapies
• Finance and capital-allocation modeling, including runway scenarios under different partnering and development paths
• Program management office support for complex cross-functional initiatives such as IND planning, partner milestones, or platform expansion